Scientists have discovered a groundbreaking method to potentially slow the progression of Alzheimer’s disease by helping brain cells repair their own DNA. Published in the journal FEBS Open Bio, a new study conducted by researchers at King’s College London demonstrates that addressing accumulated genetic wear-and-tear could serve as a novel treatment approach. Unlike traditional therapies that merely mask symptoms or slow the late-stage progression of the disease, this strategy targets the foundational cellular breakdown that causes neurons to malfunction and die as a result of aging, normal metabolic processes, and inflammation.

The research focuses on an experimental drug designated as KCL-286, which works by targeting a specific protein called retinoic acid receptor-beta (RARβ) that regulates gene expression. When tested on mice with Alzheimer’s disease, KCL-286 successfully activated this receptor, triggering a biological cascade that boosted the natural production of DNA repair proteins. Lead researcher Professor Jonathan Corcoran compared the mechanism to repairing potholes on a road—once the structural damage is fixed, cellular signaling and traffic can flow smoothly again. In addition to repairing the neurons, the drug significantly decreased brain inflammation and curbed abnormal, destructive immune cell activity.

While the primary study was conducted on animal models, early Phase 1 clinical trials have already indicated that KCL-286 is safe for human use. Researchers are highly optimistic about this innovative approach because it shifts the focus away from merely targeting amyloid plaques or tau proteins, offering a broader protective mechanism that could eventually treat a variety of neurodegenerative conditions where DNA damage is present. If subsequent funding is secured, the research team plans to launch larger human trials to definitively determine whether the drug effectively preserves memory, cognition, and daily functioning in Alzheimer’s patients.